In February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology spoke with Günter Huhle, Head of Johnson & Johnson Innovation JLABS EMEA, about Johnson & Johnson‘s approach to open innovation and its tremendous global innovation network, currently comprising ten incubators and over 420 companies that have collectively raised over US$10bn in growth capital.
Roche targets asthma with inhalable JAK1 blocker
Latest NewsResearchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
Merck appoints Jasper Bos as Managing Director of M Ventures
AppointmentsMerck today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures.
British F2G Biotech bags €24m
Latest NewsThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Bergenbio appoints Alan Barge MD as interim CMO
AppointmentsBergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
Sugar replacement slows cancer growth
Latest NewsResearchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Vertical integration: time is money
BackgroundFinancial pressure on Big Pharma and biotechs increases the need for drug developers to outsource their development and manufacturing capabilities. The CDMO and CRO sector, which is further consolidating through M&A, looks well set for continued growth. As developers have to balance the need to reduce their development risk with time to market or – for biotechs – time to next financing, contract manufacturing and contract research companies clearly favour offering fully integrated services.
Epigenetic drugs can increase tumour malignancy
Latest NewsResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
A unique approach to bring open innovation to Europe
OpinionIn February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology spoke with Günter Huhle, Head of Johnson & Johnson Innovation JLABS EMEA, about Johnson & Johnson‘s approach to open innovation and its tremendous global innovation network, currently comprising ten incubators and over 420 companies that have collectively raised over US$10bn in growth capital.
Forbion leads €40m financing in Inflazome Ltd
Latest NewsInflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
EC advisors call for update of GM legislation
Latest NewsThe EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.